U.S. Securities and Exchange Commission
                            Washington, D.C.  20549

                                  FORM 10-QSB

     [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND
                               EXCHANGE ACT OF 1934

               For the quarterly period ended September 30, 1998
 
                       Commission file number 33-16757-D

                         MEDIZONE CANADA LIMITED
           (Exact name of registrant as specified in its charter)

                 Nevada                                 87-0431771
     (State of other jurisdiction of       (I.R.S. employer identification No.)
      Incorporation or organization)

                    (Address of principal executive offices)
                         55 West 200 North, Suite 2
                             Provo, UT 84601

               (Previous Address of principal executive offices)
                              144 Buena Vista
                               P.O. Box 742
                         Stinson Beach, CA 94970


          Registrant's telephone no., including area code: (801) 377-1758


Check whether the Issuer (1) has filed all reports required to be filed by 
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for 
such shorter period that the registrant was required to file such reports), 
and (2) has been subject to such filing requirements for the past 90 
days.       Yes X     No          Yes X     No

    There were 2,250,178 common shares outstanding of the Registrant's common 
                        stock at November 12, 1998.

<PAGE>

                       MEDIZONE CANADA LIMITED AND SUBSIDIARY

                                      Index

                                 September 30, 1998

PART I - FINANCIAL INFORMATION

                                                                     Page Number

     Item 1.   Financial Statements
     Unaudited Interim Consolidated Balance Sheets                        3
     Unaudited Interim Consolidated Statements of Operations             4-5
     Unaudited Interim Consolidated Statement of Changes in
        Stockholders' Equity                                             6-11
     Notes to Unaudited Interim Consolidated Financial
        Statements                                                      11-14

     Item 2.   Management's Discussion and Analysis of Financial 
               Condition and Results of Operations                        14

PART II - OTHER INFORMATION

     Item 2.   Change in Securities                                       15
     Item 4.   Submission on Matters to a Vote of Security Holders        15
     Item 5.   Other Information                                          15
     Item 6.   Exhibits and Reports on Form 8-K                           15
               Signatures                                                 15

     
<PAGE>

                    Part 1  Financial Information

Item 1  Financial Statements

     The Financial Statements of the Registrant required to be filed with this 
10-QSB Quarterly Report were prepared by management together with Related 
Notes.  In the opinion of management, the Financial Statements fairly present 
the financial condition of the Registrant.

                           Medizone Canada Limited
                         [Development Stage Company]

                           CONDENSED BALANCE SHEETS
                                  [Unaudited]
<TABLE>
<CAPTION>

                             September 30, 1998     Dec. 31, 1997
<S>                               <C>               <C>
CURRENT ASSETS:
     Cash                              $ 29,461          $   0.00    
     Accounts Receivable                      -                 -               
     Notes Receivable                         -                 -
          Total Current Assets           29,461          $   0.00

PROPERTY AND EQUIPMENT (NET)                                 0.00

OTHER ASSETS:
     License Agreements                       0              0.00
     Organization cost (net of 
     accumulated amortization of 
     $5,520 and $5,520, respectively)         0              0.00
                
Total Other Assets                            0              0.00
                                                                     
TOTAL ASSETS                            $29,461          $   0.00


                   LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

                              September 31, 1998     Dec. 31, 1997
CURRENT LIABILITIES:
     Accounts payable                    $ 2,561          $ 9,498
     Accrued expenses                          -            1,400    
       Total Current Liabilities         $ 2,561          $10,898

Commitments and Contingencies (Note 1)

STOCKHOLDERS' DEFICIENCY:
     Common stock; authorized 
     100,000,000 shares at                 2,150           36,493
     $0.001 par value; issued and 
     outstanding 2,150,178 as 9/30/98;
     150,178 (post-split) as 12/31/97

     Additional paid-in Capital          266,599          175,797
     Deficit accumulated during the 
       development stage                (241,849)        (223,188)

Total Stockholders'Equity                 26,900          (10,898)

TOTAL LIABILITIES & EQUITY               $29,461               $0
</TABLE>

The accompanying notes are an integral part of these financial statements.
NOTE:  The balance sheet at December 31, 1997 was taken from the audited 
financial statements at that date and condensed.

<PAGE>

                           MEDIZONE CANADA LIMITED
                       [Development Stage Companies]

                      CONDENSED STATEMENTS OF OPERATIONS
                                 [Unaudited]
<TABLE>
<CAPTION>
                          For the Three     For the Three     From Inception,
                          Months Ended      Months Ended     (Nov. 18, 1987)-
                          Sept. 30, 1998    Sept. 30, 1997    Sept. 30, 1998
<S>                      <C>                <C>              <C>
REVENUE                           $   0             $   0            $      0
Cost of Goods Sold                    -                 -                   -
     Total Revenue                $   0             $   0            $      0

EXPENSES
General & Admin.                $ 7,850              $  0            $204,445
Research & Development                0                 0              29,554

    Total Expenses              $ 7,850              $  0            $233,999

NET INCOME/LOSS                ($ 7,850)             $  0           ($233,999)

</TABLE>

     The accompanying notes are an integral part of these financial statements.



<PAGE> 

                                MEDIZONE CANADA LIMITED 
                            [Development Stage Companies]

                           CONDENSED STATEMENTS OF OPERATIONS
                                       [Unaudited]

<TABLE>
<CAPTION>
                             For the Nine     For the Nine     From Inception,
                             Months Ended     Months Ended     Nov. 13, 1987 -
                             Sept. 30, 1998   Sept. 30, 1997   Sept. 30, 1998
<S>                          <C>               <C>            <C>
REVENUE                           $     0             $   0            $   0
Cost of Goods Sold                      0                 0                0
     Total Revenue                $     0             $   0            $   0

EXPENSES
General and Administrative         18,661              $  0          204,445
Research and Development                0                 0           29,554
    Total Expenses                $18,661              $  0         $233,999

INCOME FROM OPERATION                                              
                                 ($18,661)             $  0        ($233,999)

NET INCOME/LOSS                  ($18,661)             $  0        ($233,999)

</TABLE>

    The accompanying notes are an integral part of these financial statements.

<PAGE>

                             MEDIZONE CANADA LIMITED
                         [A Development Stage Company]

                Consolidated Statements of Stockholders' Equity
  From the Date of Inception (November 18, 1987) through September 30, 1998
                                    [Unaudited]          
<TABLE>
<CAPTION>                                   
                                                 Capital In  Deficit Accumulated
                                                 Excess Of    During The
                             Common Stock        Par Value  Development Stage 
                         Shares        Amount                    
<S>                      <C>           <C>       <C>          <C>
Medizone Canada Ltd.
  - Canadian

Initial issuance of 
 shares exchanged for  
 license agreement,
 Nov. 1987
($.000003 per share)    3,000,000    $     1            --              --

Common stock issued for 
 cash at $1/share 
 Nov. 1987                      1    $     1            --              --

Net loss for the year 
 ended 12/31/87                --         --            --          $(1,000)

BALANCE, Dec. 31,1987   3,000,001   $      2            --          $(1,000)

Sale of shares for 
 cash ($.7692 per
 share, no par value)     130,000   $100,000            --              --   

                        3,130,001   $100,002            --          $(1,000)

KPC Investments
 Initial capitalization 
 of KPCInvestments 
 ($.001 par value)
 July 1984 ($.003/share)  590,000   $    590      $    910              --

Shares issued for cash
 Apr.1985 ($.003/share) 3,000,000   $  3,000      $ 6, 819              --

Shares & warrants
 issued for cash
 June 1988              2,000,000   $  2,000      $ 82,089              --      

                        5,590,000   $  5,590       $89,818              --      
</TABLE>
<PAGE>
                             MEDIZONE CANADA LIMITED
                         [A Development Stage Company]

                  Consolidated Statements of Stockholders' Equity
 From the Date of Inception (November 18, 1987) through September 30, 1998
                                    [Unaudited]          
<TABLE>
<CAPTION>
                                   
                                                 Capital In  Deficit Accumulated
                             Common Stock         Excess Of      During the
                        Shares         Amount     Par Value  Development Stage  
<S>                     <C>            <C>        <C>        <C>
Medizone Canada Ltd. 
- Utah
Existing shares of MCL
 Utah (formerly KPC 
 Investments)          5,590,000     $  5,590     $    --           --

Exchange of 3,130,001
 shares of Medizone 
 Canada Ltd. - 
 Canadian for shares 
 of MCL-Utah-resulting
 in a reverse merger
 December 1988        27,132,000      $ 27,132     $ 66,551         --

Shares reserved for
 issuance to Minority
 shareholder         (1,126,888)     $ (1,127)          --          --

Shares issued for
 services 
 ($.005)/share)       1,938,000         1,938        8,062          --

Return of capital to
 majority Shareholder        --            --      (50,851)         --

Net loss for the year
 ended Dec. 31, 1988         --            --           --  $ (106,392)

BALANCE,             33,533,112        33,533      113,580  $ (107,392)
 December 31, 1988

Return of capital to
 majority Shareholder       --            --       (58,056)         --

Net loss for the year
 ended Dec. 31, 1989        --            --            --  $ ( 26,179)

BALANCE, 
 Dec. 31, 1989       33,533,112        33,533       55,524  $ (133,571)

Sale of shares for
 cash ($.05 to
 $.075/share)           983,333           983       56,517          --

</TABLE>
<PAGE>

                           MEDIZONE CANADA LIMITED
                        [A Development Stage Company]

                Consolidated Statements of Stockholders' Equity
 From the Date of Inception (November 18, 1987) through September 30, 1998
                                  [Unaudited]          

<TABLE>
<CAPTION>                                   
                                                Capital In   Deficit Accumulated
                            Common Stock         Excess Of       During the
                         Shares         Amount   Par Value   Development Stage
<S>                      <C>            <C>      <C>         <C>
Shares issued for 
 services ($.05/share)      850,000    $   850    $ 41,650                --

Shares issued to 
 minority shareholder
 which had been reserved  1,126,888      1,127          --                --

Return of capital to
 majority Shareholder            --         --     (42,480)               --

Net loss for the year
 ended Dec. 31, 1990             --         --          --          $ (28,561)

BALANCE, Dec. 31, 1990   36,493,333     36,493   $ 111,211          $(162,132)

Capital received from
 majority Shareholder            --         --   $   9,100                 --

Net loss for the year 
 ended Dec. 31, 1991             --         --          --          $  (8,150)  
     
BALANCE, Dec. 31, 1991   36,493,333     36,493   $ 120,311         $ (170,282)

Capital received from 
 majority shareholder            --         --   $   6,314                  --
     
Net loss for the year 
 ended Dec. 31, 1992             --         --          --        $    (8,334)
     
Balance, Dec. 31, 1992   36,493,333    $36,493   $ 126,625        $  (178,616)

Capital received from 
 majority shareholder            --         --   $  25,936                  --
     
Net loss for the year
 ended Dec. 31, 1993             --         --          --         $  (32,357)

Balance, Dec. 31, 1993   36,493,333    $36,493   $ 152,561         $ (210,973)

</TABLE>
<PAGE>
                               MEDIZONE CANADA LIMITED
                           [A Development Stage Company]

                   Consolidated Statements of Stockholders' Equity
 From the Date of Inception (November 18, 1987) through September 30, 1998 
                                     [Unaudited]          
<TABLE>
<CAPTION>                                   
                                                Capital In   Deficit Accumulated
                              Common Stock       Excess Of      During the
                            Shares     Amount    Par Value   Development Stage
<S>                         <C>        <C>      <C>           <C> 
Capital received from 
 majority shareholder             --        --   $  12,038                  --

Net loss for the year 
 ended Dec. 31, 1994              --        --          --         $   (3,617)
     
Balance, Dec. 31, 1994    36,493,333    36,493    $164,599         $ (214,590)

Capital received from 
 majority shareholder             --        --    $  5,553                  --

Net loss for the year 
 ended Dec. 31, 1995              --        --          --        $    (3,553)

Balance, Dec. 31, 1995    36,493,333    36,493    $170,152        $  (218,143)

Capital received from 
 majority shareholder             --        --       3,301                  --

Net loss for the year 
 ended Dec. 31, 1996              --        --          --        $    (3,301)  

Balance, Dec. 31, 1996    36,493,333    36,493    $173,453        $  (221,444)

Capital received from
 majority shareholder             --        --       2,334                  --

Net loss for the year
 ended Dec. 31, 1997              --        --          --        $    (1,744)

Balance, Dec. 31, 1997    36,493,333   $36,493    $175,797        $  (223,188)

Capital received from 
 majority shareholder             --        --    $ 11,469                  --

Reverse Stock Split 1:243
 retaining 100,000,000 
 shares at a par value
 $.001; June 10, 1998    (36,343,154)  ($36,343)    36,343                  --

</TABLE>
<PAGE>

                             MEDIZONE CANADA LIMITED
                         [A Development Stage Company]

                Consolidated Statements of Stockholders' Equity
  From the Date of Inception (November 18, 1987) through September 30, 1998
                                  [Unaudited]          
<TABLE>
<CAPTION>                                   
                                             Capital In    Deficit Accumulated
                            Common Stock      Excess Of          During the
                         Shares     Amount    Par Value     Development Stage   
<S>                     <C>        <C>       <C>           <C> 
Sale of Shares for
 Cash; June 10, 1998   1,000,000  $  1,000     $ 19,000                    --

Sale of Shares for
 Cash; August, 1998    1,000,000  $  1,000     $ 24,000

Net loss for the nine
 months ended 9/30/98         --        --           --            $  (18.661)

Balance, 
 September 30, 1998    2,150,178  $  2,150     $266,599            $  (241,849)

</TABLE>

<PAGE>

                           MEDIZONE CANADA LIMITED
                       (A Development Stage Company)

           Notes to Unaudited Consolidated Financial Statements

                           September 30, 1998

Note 1 - Summary of Significant Accounting Policies

Condensed Financial Statements- The accompanying financial statements have 
been prepared by the Company without audit.  In the opinion of management, all 
adjustments (which include only normal recurring adjustments) necessary to 
present fairly the financial position, results of operations, cash flows at 
September 30, 1998, and for all the periods presented have been made.

Certain information and footnote disclosures normally included in financial 
statements prepared in accordance with generally accepted accounting 
principles have been condensed or omitted.  It is suggested that these 
condensed financial statements be read in conjunction with the financial 
statements and notes thereto included in the Company's December 31, 1997, 
audited financial statements.  The results of operations for the period ended 
September 30, 1998, are not necessarily indicative of the operation results for
the full year.

Organization - Medizone Canada Limited, a Nevada corporation (the "Company" or 
the "Registrant") was organized in 1987 and is a development stage company.  
The company was a majority owned subsidiary of Medizone International, Inc. 
("MII") until June, 1998.   MII is a Nevada corporation, organized in 1986, 
whose objective is to (1) gain regulatory approval for its drug, a precise 
mixture of ozone and oxygen called MEDIZINE (R), and its process of 
inactivating lipid enveloped viruses for the intended purpose of 
decontaminating blood and blood products and assisting in the treatment of 
certain diseases; and (ii) develop the related technology and equipment for 
the medical application of its products, including its drug production and 
delivery system (the "Medizone Technology").  The Company is not currently 
engaged in any business activity, but is seeking potential investments or 
business acquisitions and consequently is considered a developmental stage 
company as defined in SFAS No. 7.  The Company has, at the present time, not 
paid any dividends and any dividends that may be paid in the future will 
depend upon the financial requirements of the Company and other relevant 
factors.

Accounting Estimates - The preparation of the financial statements in 
conformity with generally accepted accounting principles requires management 
to make estimates and assumptions that affect the reported amounts of assets 
and liabilities, the disclosures of contingent assets and liabilities at the 
date of the financial statements and the reported amount of revenues and 
expenses during the reporting period.  Actual results could differ from those 
estimated.

Stock Split - On June 10, 1998 the Board of Directors ratified a resolution to 
reverse split the Company's outstanding common voting stock on a basis of one 
for 243, while retaining the authorized shares at 100,000,000 and the par 
value at $0.001.

Note 2 - Related Party Transactions

Management Compensation - During the periods presented the Company paid Brenda 
M. Hall, the company's director and president $1,000 per month.  The Company
paid Paul Finlayson, director, $250 for the quarter and Pamela Price, director,
$500 for the quarter.

<PAGE>
NOTE 3 -   DISCONTINUED OPERATIONS

     None

Note 4 - Common Stock

Unless otherwise stated, all transactions shown below were with unrelated 
parties and the securities issued were restricted:

In July 1984, KPC initially issued 590,000 shares in a private transaction to 
shareholders no longer affiliated with the Company for proceeds of $1,500.

In April 1985, KPC issued 3,000,000 shares of common stock in a public 
offering for net proceeds after offering costs of $9,819.

In June 1988, KPC issued 2,000,000 units consisting of one share of common 
stock and two warrants which allow the holder to purchase one share of common 
stock per warrant.  The warrants were exercisable at $.125 per share and 
expired on December 31, 1997.  The net proceeds of this offering were $84,089.

In December 1988, KPC reserved 27,200,000 shares for issuance to the 
stockholders of MedCan in exchange for all the shares of MedCan.  Of this 
amount, 26,005,112 shares were so exchanged and 1,126,888 shares were 
reserved.  Also during 1988, 1,938,000 shares were issued to a consultant for 
services rendered with a value of $10,000.

In 1990, the Company issued 983,333 shares of common stock at prices ranging 
from $.05 to $.075 in private offerings to two individuals unrelated to the 
Company for proceeds of $57,400.  The Company also issued, for services 
rendered, 850,000 shares to five individuals, 550,000 shares to the three 
directors of the Company, 50,000 shares to an employee, and 250,000 shares to 
a consultant, to which it assigned the value of $.05 per share for an 
aggregate of $42,500.

During 1990, the 1,126,888 shares reserved in December 1988 for issuance to 
the remaining stockholder of MedCan in exchange for the shares of MedCan were 
issued.

On June 10, 1998, the Board of Directors effectuated a reverse split on a 
basis of one for 243, while retaining the authorized shares at 100,000,000 and 
the par value at $0.001.  Additionally, on June 10, 1998, the Company issued 
1,000,000 post-split shares of its "unregistered" and "restricted" common 
stock to the appointed Director and President, Brenda M. Hall, in 
consideration of the sum of $20,000 cash, effectively passing control (87%) to 
the new officer.  

During the end of August, 1998, the Company issued 1,000,000 shares of common
stock at $.025 per share in a private offering to 5 individuals for proceeds of
$25,000.  Four of the individuals were unrelated to the Company.  The fifth 
individual, Brenda Hall, the company's sole director and officer, bought 
250,000 shares of the private offering.

<PAGE>
NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared in conformity with 
generally accepted accounting principles which contemplate continuation of the 
Company as a going concern.  However, the Company has incurred losses since 
inception, has expended most of its working capital and has not yet been 
successful in establishing profitable operations.  These factors raise 
substantial doubt about the ability of the Company to continue as a going 
concern.  In this regard, management is proposing to raise additional funds 
through loans and/or through additional sales of it common stock or through 
the acquisition of another company by issuing common stock.  There is no 
assurance that the Company will be successful in raising this additional 
capital.

The financial statements do not include any adjustments relating to the 
recoverability and classification of recorded asset amounts or the amounts and 
classification of liabilities that might be necessary should the company be 
unable to obtain additional financing or establish profitable operation.

NOTE 6 - CONTINGENCIES

NONE

NOTE 7 - SUBSEQUENT EVENTS

On October 1, 1998, the company issued 100,000 S-8 common shares to consultants
pursuant to "Consultant Compensation Agreement No.1"  The shares were registered
on Form S-8 with the Securities Exchange Commission on October 2, 1998.

On October 30, 1998, Paul Finlayson tendered his resignation as secretary/
treasurer and director of the company.  This action leaves Brenda M. Hall as
sole officer and director of the company.

ITEM 2

          MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                           AND RESULTS OF OPERATIONS

                            Results of Operations
    Nine-month Periods ended September 30, 1998, and September 30, 1997

     No research and development expenses were incurred in 1998 or 1997.  For 
the nine month period ending September 30, 1998, nominal general and 
administrative expenses totaling $18,661 were incurred for shareholder costs,
legal fees and taxes. General and administrative expenses during the nine month 
period ending September 30, 1997, were $0.

                     Liquidity and Capital Resources

     For the three month period ending September 30, 1998, the Company had a 
working capital deficiency of ($7,850) and a shareholders' deficiency of 
($7,850).  The Company had a working capital deficiency of ($18,661) and 
shareholders' deficiency of ($18,661) for the nine month period ending September
30, 1998.  At December 31, 1997, the Company had a working capital deficiency
of($0.00) and a shareholders' deficiency of ($0.00).

PART II - OTHER INFORMATION

ITEM 1     Legal Proceedings
                 None

ITEM 2     Change in Securities
     
     During the end of August the company successfully completed a private 
offering of 1,000,000 common shares for $25,000 cash.

ITEM 3     Defaults on Senior Securities
                 None

ITEM 4     Submission on Matters to a Vote of Security Holders
     

ITEM 5     Other Information

     On August 28, 1998, Pamela Price resigned as Vice-President and Director of
the company.

ITEM 6     Exhibits and Reports on Form 8-K

                 None 

                                        SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934,
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.

                                       MEDIZONE CANADA LIMITED
                                       (Registrant)
                                       /s/ Brenda M. Hall
                                       President and Director
                                       November 13, 1998